Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.58 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.50 |
| ▸ | CCR7 | P32248 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538310 | 1.00 | CXCR2 (0.58) | CXCR2CXCR1CCR7 | |
| Azd-5122 SCHEMBL3180355 | 0.80 | CXCR2 (0.83) | CXCR2CXCR1 | |
| Azd-5122 SCHEMBL29393328 | 0.80 | CXCR2 (0.83) | CXCR2CXCR1 | |
| Azd-5122 SCHEMBL3183036 | 0.80 | CXCR2 (0.83) | CXCR2CXCR1 | |
| SCHEMBL13528031 | 0.80 | CXCR2 (0.62) | CXCR2CXCR1CCR7 | |
| Azd-5122 SCHEMBL13538314 | 0.80 | CXCR2 (0.83) | CXCR2CXCR1 | |
| Azd-5122 SCHEMBL20452735 | 0.80 | CXCR2 (0.83) | CXCR2CXCR1 | |
| Azd-5122 SCHEMBL3171248 | 0.80 | CXCR2 (0.83) | CXCR2CXCR1 | |
| Azd-5122 SCHEMBL3180319 | 0.80 | CXCR2 (0.83) | CXCR2CXCR1 | |
| SCHEMBL490032 | 0.78 | CXCR2 (0.47) | CXCR2CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010007427-A1 | PYRIMIDYL SULFONAMINDE DERIVATIVE AND ITS USE FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016275-A1 | NOVEL COMPOUND 395 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016275-A1 | NOVEL COMPOUND 395 | CCL5, CCL2, CCL11 | CXCR2 5/4885CXCR1 7/4885CCR7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.